Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–63 of 63 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Ethinyl Estradiol / Norgestimate Oral Tablet Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

NCT01790087
View directory record Official record
Conditions
Healthy
Interventions
ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 5, 2026, 6:07 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Effects of SQ109 on QTc Interval in Healthy Subjects

NCT01874314
View directory record Official record
Conditions
Tuberculosis
Interventions
SQ109, SQ109 Placebo, Moxifloxacin
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 24, 2014 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

NCT00357604
View directory record Official record
Conditions
HIV Infections
Interventions
Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 8, 2011 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect Of WCK 2349 on the QT/QTc Interval in Health Volunteers

NCT02217930
View directory record Official record
Conditions
Qt Interval, Variation in
Interventions
WCK 2349, Placebo, Moxifloxacin
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 29, 2015 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

AZD3293 Thorough QT Study in Healthy Male Volunteers

NCT02040987
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AZD3293, Placebo, Moxifloxacin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Receptor Antagonist
Interventions
CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Cardiac Conduction of GSK1349572

NCT00996021
View directory record Official record
Conditions
Healthy Subjects
Interventions
GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 25, 2010 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo

NCT01191723
View directory record Official record
Conditions
Healthy
Interventions
MAP0004, Inhaler Placebo, Moxifloxacin, Placebo Capsule
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 45 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study To Evaluate The Effect Of Single Intravenous Doses Of Tigecycline On QTc Intervals In Healthy Subjects

NCT01287793
View directory record Official record
Conditions
Healthy
Interventions
tigecycline, moxifloxacin, 100 mL 0.9% Sodium Chloride intravenous, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 24, 2011 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 3 Interventional Results available

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

NCT02679573
View directory record Official record
Conditions
Community Acquired Bacterial Pneumonia
Interventions
Delafloxacin, Moxifloxacin, Linezolid
Drug
Lead sponsor
Melinta Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
25
States / cities
Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2020 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Oral Contraceptives, Insulin Resistance and Cardiovascular Risk Profile in Pre-Menopausal Women

NCT01475513
View directory record Official record
Conditions
Insulin Sensitivity, Cardiovascular Risk, Perimenopausal Disorder
Interventions
Ortho Cyclen®
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 5, 2026, 6:07 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Hormone Replacement for Premature Ovarian Insufficiency

NCT02922348
View directory record Official record
Conditions
Primary Ovarian Insufficiency
Interventions
Hormone Replacement Therapy, Combined Oral Contraceptives
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
14 Years to 45 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

NCT03155893
View directory record Official record
Conditions
Healthy
Interventions
ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Premature Discontinuation of Contraceptive Implants

NCT04828824
View directory record Official record
Conditions
Contraception Behavior
Interventions
Ethinyl Estradiol / Norgestimate Oral Tablet
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
14 Years to 23 Years · Female only
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 5, 2026, 6:07 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)

NCT01787357
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin (JNJ-28431754), Placebo, Moxifloxacin
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 29, 2016 · Synced Oct 5, 2026, 6:07 PM EDT